Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9920148 | 0.88 | MEN1 (0.67) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL15613023 | 0.76 | MEN1 (0.69) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL27179466 | 0.74 | MEN1 (0.65) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL30926533 | 0.74 | MEN1 (0.65) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL4250041 | 0.73 | ALDH1A1 (0.80) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL27179416 | 0.71 | SIRT2 (0.84) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL1001981 | 0.69 | SMN1; SMN2 (0.54) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL15503709 | 0.69 | NPC1 (1.00) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL12412117 | 0.69 | L3MBTL1 (0.58) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL26336375 | 0.68 | MEN1 (0.71) | MEN1KMT2AALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143269-B2 | Inhibitors of store operated calcium release | CALCIMEDICA, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143269-B2 | Inhibitors of store operated calcium release | CALCIMEDICA, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100087415-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087415-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087415-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | ORAI1, SARAF, RYR2 | MEN1 3485/4885KMT2A 4780/4885ALDH1A1 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.